0000000000451340

AUTHOR

Marta Benavent Viñuales

showing 2 related works from this author

Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt)…

2013

3551 Background: KRAS wt mCRC pts progressing on chemotherapy and anti-EGFR mAbs have limited treatment options. Sym004 is a first-in-class drug mixture of two mAbs targeting non-overlapping epitopes on the EGFR, causing its internalization and degradation. With this unique mechanism of action, Sym004 overcomes acquired resistance to anti-EGFR mAbs in preclinical studies. Methods: Open-label, multicenter trial assessing safety (primary endpoint) and efficacy of 2 dose levels of Sym004 in KRAS wt mCRC pts with prior clinical benefit to anti-EGFR mAbs and subsequent progression during or within 6 months after treatment cessation. Sym004 was administered until disease progression or unaccepta…

Cancer ResearchChemotherapybusiness.industryColorectal cancermedicine.drug_classmedicine.medical_treatmentWild typemedicine.diseasemedicine.disease_causeMonoclonal antibodyOncologyRefractoryImmunologyCancer researchMedicineIn patientKRASAnti-EGFR Monoclonal AntibodybusinessJournal of Clinical Oncology
researchProduct

Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resista…

2014

3551 Background: Preclinical models suggest that WT KRAS mCRC may retain EGFR dependency despite resistance developed to anti-EGFR mAb treatment (eg, cetuximab or panitumumab). Sym004 is the first-...

Cancer ResearchCetuximabColorectal cancermedicine.drug_classbusiness.industrymedicine.diseaseMonoclonal antibodymedicine.disease_causedigestive system diseasesOncologymedicineCancer researchPanitumumabIn patientKRASAnti-EGFR Monoclonal Antibodybusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct